BLUE

0.333

3.80% 0.0122

Handel nachbörslich: .32 -0.013 -3.90%

Bluebird Bio Inc (BLUE)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt BLUE? Forum Prognose

Schlusskurs vom Vortag:

$0.3208

Offen:

$0.3241

24-Stunden-Volumen:

3.55M

Relative Volume:

0.53

Marktkapitalisierung:

$75.10M

Einnahmen:

$21.73M

Nettoeinkommen (Verlust:

$-91.17M

KGV:

-0.3265

EPS:

-1.02

Netto-Cashflow:

$-286.43M

1W Leistung:

-17.84%

1M Leistung:

-32.15%

6M Leistung:

-67.67%

1J Leistung:

-90.26%

1-Tages-Spanne:

$0.315

$0.3365

1-Wochen-Bereich:

$0.315

$0.4296

52-Wochen-Spanne:

$0.315

$5.53

Bluebird Bio Inc Stock (BLUE) Company Profile

Firmenname

Bluebird Bio Inc

Sektor

Healthcare (1196)

Branche

Biotechnology (683)

Telefon

339-499-9300

Adresse

455 GRAND UNION BOULEVARD, SOMERVILLE, MA

Mitarbeiter

Twitter

@bluebirdbio

Nächster Verdiensttermin

2024-11-05

Neueste SEC-Einreichungen

BLUE's Discussions on Twitter

Vergleichen Sie BLUE mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
BLUE	0.333	75.10M	21.73M	-91.17M	-286.43M	-1.02
VRTX	467.01	119.87B	10.63B	-479.80M	-1.35B	13.33
REGN	762.00	83.27B	13.85B	4.65B	3.32B	35.06
ARGX	567.90	33.96B	1.86B	-40.29M	-1.28B	-4.16
ALNY	232.27	30.18B	2.09B	-332.26M	16.06M	-4.14
BNTX	101.87	24.42B	3.30B	-501.07M	1.03B	11.54

Bluebird Bio Inc Stock (BLUE) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2023-04-28	Eingeleitet	JP Morgan	Overweight
2023-03-07	Eingeleitet	Robert W. Baird	Outperform
2022-08-05	Hochstufung	Barclays	Underweight → Equal Weight
2022-08-02	Hochstufung	Raymond James	Mkt Perform → Outperform
2022-04-06	Herabstufung	Cowen	Outperform → Market Perform
2022-03-07	Herabstufung	Barclays	Equal Weight → Underweight
2021-11-08	Bestätigt	Barclays	Equal Weight
2021-11-08	Bestätigt	Canaccord Genuity	Hold
2021-11-08	Herabstufung	Goldman	Neutral → Sell
2021-11-08	Herabstufung	Morgan Stanley	Equal-Weight → Underweight
2021-11-08	Bestätigt	RBC Capital Mkts	Sector Perform
2021-11-08	Bestätigt	Wedbush	Neutral
2021-11-08	Bestätigt	Wells Fargo	Equal Weight
2021-08-10	Herabstufung	Canaccord Genuity	Buy → Hold
2021-08-10	Herabstufung	Goldman	Buy → Neutral
2021-08-10	Herabstufung	Wells Fargo	Overweight → Equal Weight
2021-08-10	Fortgesetzt	William Blair	Mkt Perform
2021-08-09	Herabstufung	SVB Leerink	Outperform → Mkt Perform
2021-07-01	Herabstufung	Berenberg	Buy → Hold
2021-03-10	Hochstufung	Mizuho	Neutral → Buy
2021-02-17	Herabstufung	JP Morgan	Overweight → Neutral
2021-02-16	Herabstufung	BofA Securities	Buy → Neutral
2021-02-16	Herabstufung	Wedbush	Outperform → Neutral
2021-02-16	Herabstufung	William Blair	Outperform → Mkt Perform
2020-12-09	Herabstufung	Maxim Group	Buy → Hold
2020-11-11	Eingeleitet	Berenberg	Buy
2020-11-05	Herabstufung	BMO Capital Markets	Outperform → Market Perform
2020-11-05	Herabstufung	Barclays	Overweight → Equal Weight
2020-11-05	Herabstufung	Stifel	Buy → Hold
2020-11-02	Hochstufung	William Blair	Mkt Perform → Outperform
2020-10-20	Eingeleitet	Mizuho	Buy
2020-05-13	Eingeleitet	RBC Capital Mkts	Outperform
2020-03-27	Hochstufung	Stifel	Hold → Buy
2020-02-19	Herabstufung	Raymond James	Outperform → Mkt Perform
2020-02-03	Fortgesetzt	BofA/Merrill	Buy
2020-02-03	Hochstufung	Evercore ISI	In-line → Outperform
2019-12-13	Hochstufung	Oppenheimer	Perform → Outperform
2019-11-26	Hochstufung	SVB Leerink	Mkt Perform → Outperform
2019-11-19	Herabstufung	Evercore ISI	Outperform → In-line
2019-11-04	Hochstufung	Wedbush	Neutral → Outperform
2019-10-01	Eingeleitet	Stifel	Hold
2019-08-12	Herabstufung	William Blair	Outperform → Mkt Perform
2019-06-18	Hochstufung	Maxim Group	Hold → Buy

Alle ansehen

Bluebird Bio Inc Aktie (BLUE) Neueste Nachrichten

08:02 AM

Layoff Tracker: Adaptimmune Downsizes by 33% in Strategic Realignment - BioSpace

08:02 AM

05:06 AM

bluebird bio Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance

Nov 16, 2024

Nov 15, 2024

Earnings Snapshot: bluebird bio reports mixed Q3, Q4 revenue outlook below consensus - MSN

Nov 15, 2024

JP Morgan Downgrades Gene Therapy Focused Bluebird Bio, Cites Limited Funding Options - AOL

Nov 15, 2024

Royal Bank of Canada Reaffirms "Sector Perform" Rating for bluebird bio (NASDAQ:BLUE) - MarketBeat

Nov 15, 2024

bluebird bio extends selloff as BofA and J.P. Morgan cut after Q3 results - MSN

Nov 15, 2024

bluebird bio downgraded by Bank of America, shares tumble - Proactive Investors USA

Nov 15, 2024

bluebird bio stock cut at BofA and J.P. Morgan (BLUE:NASDAQ) - Seeking Alpha

Nov 15, 2024

bluebird bio (NASDAQ:BLUE) Price Target Lowered to $2.00 at Barclays - MarketBeat

Nov 15, 2024

Bluebird bio stock plunges to 52-week low of $0.34 - Investing.com

Nov 15, 2024

Bluebird bio stock plunges to 52-week low of $0.34 By Investing.com - Investing.com UK

Nov 15, 2024

bluebird bio (NASDAQ:BLUE) Downgraded to "Neutral" Rating by Bank of America - MarketBeat

Nov 15, 2024

JPMorgan Chase & Co. Downgrades bluebird bio (NASDAQ:BLUE) to Underweight - MarketBeat

Nov 15, 2024

bluebird bio, Inc. (NASDAQ:BLUE) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 15, 2024

bluebird bio, Inc.'s (NASDAQ:BLUE) Revenues Are Not Doing Enough For Some Investors - Simply Wall St

Nov 15, 2024

Bluebird: Q3 Earnings Snapshot - Darien Times

Nov 15, 2024